Noom LegitScript and Accreditation Status: What Patients Should Know

What LegitScript Certification Actually Means for Noom

LegitScript's "Telehealth Provider" seal confirms that a platform submitted documentation showing valid business registration, licensed practitioners, and a written compliance program. It does not certify clinical quality, prescribing appropriateness, or patient outcomes. Noom obtained this designation, which places it in the same verification tier as other certified digital health companies, but certification is not equivalent to accreditation by a body such as URAC or NCQA.

What LegitScript Reviews

LegitScript reviews identity documents, practitioner license numbers, terms of service, and privacy policies. According to LegitScript's own published criteria for telehealth certification, a platform must demonstrate that clinicians are licensed in the states where they practice and that the site does not advertise or dispense controlled substances illegally. LegitScript's healthcare merchant certification standards are publicly posted at their domain, though it is not on the HealthRX citation allow-list; the FDA collaborates with LegitScript on illegal online pharmacy enforcement.

The FDA's BeSafeRx program lists LegitScript as a verification partner for identifying rogue online pharmacies. Noom Med does not operate a dispensing pharmacy directly. It routes prescriptions to third-party pharmacies, which means the LegitScript telehealth seal does not extend to those dispensing partners. Patients should verify their assigned pharmacy independently through the FDA's approved verification tools [1].

What LegitScript Does Not Review

LegitScript does not audit:

• Prescribing appropriateness for individual patients
• Clinical protocol adherence (for example, whether BMI thresholds match FDA labeling)
• Follow-up care quality
• Adverse event monitoring

The FDA-approved labeling for semaglutide injection (Wegovy) specifies use in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity [2]. Whether any individual telehealth platform consistently applies that threshold requires chart-level auditing that LegitScript does not perform.

URAC and NCQA as Complementary Standards

URAC offers a Health Website Accreditation and a Telehealth Accreditation program. NCQA certifies patient-centered medical homes and managed care organizations. As of the date of this review, Noom has not published URAC or NCQA accreditation credentials on its website. Absence of those credentials does not make the service unsafe, but it does mean no independent body has audited clinical workflow quality at Noom.

Noom's BBB Record and Consumer Complaint Patterns

The Better Business Bureau profile for Noom, Inc. Shows a pattern of billing-related complaints that the editorial team reviewed in January 2025. The BBB is not a regulatory agency, but complaint volume and resolution patterns signal operational risk for prospective patients.

Volume and Categories

As of early 2025, Noom's BBB file contains several hundred closed complaints over a three-year rolling window. The dominant categories are:

• Billing and collection disputes (most frequent)
• Auto-renewal charges after cancellation requests
• Difficulty obtaining refunds within stated policy windows
• Delayed or absent responses from customer support

The Federal Trade Commission's guidelines on negative option marketing, updated in 2023, require that companies making subscription offers clearly disclose renewal terms and provide simple cancellation mechanisms [3]. Billing complaint density at Noom suggests that some patients find those requirements inconsistently applied in practice.

How to Read BBB Ratings in Context

A BBB letter grade reflects complaint volume relative to company size and whether complaints were resolved, not the safety or efficacy of the medical service. Noom's rating has fluctuated. Patients considering Noom should treat the BBB record as one signal among several, weighting it more heavily for subscription-management risk than for clinical safety assessment.

Noom Med: GLP-1 Prescribing and Regulatory Framework

Noom launched Noom Med as its prescription weight-loss arm. Through Noom Med, asynchronous or synchronous telehealth visits can result in prescriptions for GLP-1 receptor agonists, including semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda). This section reviews the regulatory framework governing those prescriptions.

FDA Approval Status of Drugs Prescribed

Wegovy (semaglutide 2.4 mg, subcutaneous, once weekly) received FDA approval for chronic weight management in June 2021 [2]. Saxenda (liraglutide 3.0 mg, subcutaneous, daily) received FDA approval for the same indication in December 2014 [4]. Both carry FDA-required Risk Evaluation and Mitigation Strategy (REMS) communications about thyroid C-cell tumor risk observed in rodent studies.

The clinical evidence supporting semaglutide is substantial. In STEP-1 (N=1,961), semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001) [5]. In STEP-4 (N=803), participants who continued semaglutide maintained their weight loss, while those switched to placebo regained an average of 6.9 percentage points of body weight over 48 weeks [6]. These trial results apply to the drug molecule, not to any specific telehealth delivery model.

Compounded Semaglutide Risk

During the FDA-declared shortage period for Wegovy, some telehealth platforms prescribed compounded semaglutide from 503B outsourcing facilities or 503A compounding pharmacies. The FDA issued a shortage determination update in 2024 clarifying that the shortage for tirzepatide (Zepbound/Mounjaro) was resolved and that compounding of these GLP-1 agents outside shortage conditions may violate federal law [7]. Patients using Noom Med should confirm whether any semaglutide they receive is FDA-approved branded product or a compounded formulation, and if compounded, whether the compounding pharmacy holds a valid 503B registration [7].

Telehealth Prescribing Regulations

GLP-1 receptor agonists are not controlled substances under the Controlled Substances Act, meaning prescribers do not face the same Ryan Haight Act restrictions that apply to stimulants or benzodiazepines. A DEA registration is not required to prescribe semaglutide via telehealth. However, prescribers must be licensed in the state where the patient is located at the time of the visit. Noom's prescribers operate under this state-by-state framework. The Federation of State Medical Boards published updated telehealth policy guidelines in 2022 noting that "the practice of medicine occurs where the patient is located" [8].

Clinical Evidence: Noom's Behavioral Program Versus Drug-Only Models

Noom's core product is a cognitive behavioral therapy (CBT)-informed app combined with human coaching, layered under a subscription model. The company has published its own internal research, but the peer-reviewed evidence base for Noom's specific protocol is thinner than the evidence base for the GLP-1 drugs it now co-prescribes.

Published Research on Noom's App-Based Program

A randomized controlled trial published in JMIR mHealth and uHealth (N=61) found that participants using a Noom-like smartphone app with coaching showed modest weight loss at 12 weeks compared to a self-monitoring-only group, though the sample size limits generalizability [9]. A larger retrospective analysis published in Scientific Reports (N=35,921 Noom users) found a mean weight loss of 7.6% at 78 weeks among users who logged food for at least half the days in the program, but this was observational data with significant selection bias [10].

The American College of Cardiology and American Heart Association's 2013 guidelines on lifestyle management, which remain a reference standard, recommend at least 150 minutes per week of moderate-intensity physical activity and dietary sodium reduction as components of cardiovascular risk reduction [11]. Noom's program addresses dietary behavior change but does not specifically target AHA-recommended activity thresholds as a measurable outcome.

Where Behavioral Intervention and GLP-1 Therapy Overlap

The SCALE Obesity and Prediabetes trial (N=3,731) tested liraglutide 3.0 mg combined with lifestyle counseling and showed 8.0% mean weight loss at 56 weeks versus 2.6% with placebo plus lifestyle counseling (P<0.001) [12]. This confirms that drug plus behavioral support outperforms either alone. Whether Noom's specific coaching model provides additive benefit on top of GLP-1 therapy has not been tested in a published randomized trial.

The HealthRX clinical team proposes the following framework for evaluating any telehealth weight-loss platform combining behavioral coaching with GLP-1 prescribing:

1. Is the prescribing provider licensed in your state?
2. Is the GLP-1 medication FDA-approved branded product or a compounded formulation?
3. Does the platform have a protocol for monitoring thyroid function, pancreatitis symptoms, and heart rate increases documented in GLP-1 labeling?
4. What is the escalation pathway if you experience a serious adverse event?
5. Does the behavioral coaching program have peer-reviewed evidence separate from the drug's own trial data?

If a platform cannot answer all five questions clearly in writing, patients should seek a second opinion from a board-certified endocrinologist or obesity medicine physician.

State Licensing and Pharmacy Verification

Noom does not hold a pharmacy license and does not dispense medications from its own facility. Prescriptions generated through Noom Med are transmitted to third-party pharmacies. The choice of pharmacy may affect whether the patient receives an FDA-approved product, a compounded product, or a biosimilar when one becomes available.

How to Verify Your Pharmacy

The FDA's BeSafeRx program provides a database of verified online pharmacies through the National Association of Boards of Pharmacy (NABP) [1]. The NABP's ".pharmacy" domain accreditation and VIPPS (Verified Internet Pharmacy Practice Sites) program are the strongest indicators that a dispensing pharmacy meets federal and state standards. Patients should confirm their assigned Noom Med pharmacy holds either VIPPS accreditation or a valid NABP ".pharmacy" credential before filling a prescription.

State Medical Board Complaints

State medical boards maintain disciplinary records for licensed physicians and nurse practitioners. If a patient has a concern about clinical care received through Noom Med, the appropriate escalation path is a complaint to the medical board of the state where the prescribing clinician holds their license. The Federation of State Medical Boards provides a directory of all state boards [8]. The FTC handles billing and marketing complaints, while the FDA's MedWatch program accepts adverse event reports related to medications [13].

How Noom Compares to NCQA-Accredited Obesity Programs

NCQA accredits a small number of intensive behavioral therapy programs for obesity. CMS covers intensive behavioral therapy for obesity under Medicare Part B, defined as a minimum of 22 face-to-face visits in the first year with a physician or other qualified practitioner [14]. Noom's asynchronous coaching model does not meet the CMS definition of intensive behavioral therapy, meaning it is generally not reimbursable under Medicare Part B as a medical service.

Private insurance reimbursement for Noom varies by plan. The AHA and ACC have both noted that structured lifestyle interventions with frequent contact (defined as more than 14 sessions in six months) produce clinically meaningful weight loss of approximately 5% to 8% [11]. Noom's contact frequency, via app interactions and scheduled coaching calls, may or may not meet that threshold depending on how actively a given patient engages.

Billing Practices and FTC Compliance

The FTC's 2023 Negative Option Rule amendments require that subscription services provide a simple mechanism for cancellation that is at least as easy as the sign-up process [3]. Multiple consumer complaints on the BBB and on the FTC's Consumer Sentinel Network allege that Noom's cancellation process involves multiple confirmation steps, waiting periods, or direct phone contact requirements that complicate the process.

Noom's terms of service, as reviewed in January 2025, state that cancellations must be processed through the in-app settings or by contacting support. The FTC has taken enforcement actions against other subscription-based health and wellness companies for similar practices, most notably in its 2023 action against Amazon's Prime subscription service and its ongoing monitoring of negative option practices across the digital health sector [3].

Patients who believe they were charged improperly should file a complaint with the FTC at reportfraud.ftc.gov and dispute the charge through their credit card issuer under the Fair Credit Billing Act.

What Independent Physicians Say About App-Based GLP-1 Programs

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity states: "We recommend that anti-obesity pharmacotherapy be used as an adjunct to lifestyle therapy (dietary modification and increased physical activity) and not as the sole intervention" [15]. This supports the conceptual basis of combining a behavioral app with GLP-1 therapy, but the guideline also specifies that pharmacotherapy should be managed by clinicians with training in obesity medicine.

The American Board of Obesity Medicine (ABOM) certifies physicians who have demonstrated competency in obesity treatment. Patients using Noom Med or any telehealth GLP-1 platform should ask whether their assigned prescriber holds ABOM certification or equivalent specialist training. Noom does not publicly disclose the specialty training of its prescribing clinicians as a standard part of its onboarding flow.

Adverse Event Reporting and Safety Monitoring at Noom

FDA-approved labeling for Wegovy lists the following adverse events occurring in at least 5% of trial participants: nausea (44.2%), diarrhea (29.7%), vomiting (24.5%), constipation (24.2%), and abdominal pain (20.0%) [2]. More serious risks include pancreatitis, gallbladder disease, increased heart rate, and a theoretical risk of medullary thyroid carcinoma based on rodent data.

The FDA's MedWatch program allows patients and providers to report suspected adverse events from any prescription medication [13]. Noom Med's onboarding documentation should include a clear adverse event reporting pathway. Patients who develop severe abdominal pain, persistent vomiting, or a palpable neck mass while using a GLP-1 agent should seek emergency care and report the event to MedWatch.

Summary of Accreditation and Compliance Signals

The table below consolidates the key compliance signals for Noom as evaluated for this review.

| Signal | Status | What It Means | |---|---|---| | LegitScript Telehealth Certification | Active (2024) | Identity and licensure verified; clinical quality not audited | | BBB Accreditation | Not accredited (rated B+) | Complaint volume moderate; billing disputes predominate | | URAC Telehealth Accreditation | Not published | No independent clinical workflow audit | | NCQA Accreditation | Not published | No independent quality measurement | | FDA-approved drug prescribing | Yes (Wegovy, Saxenda) | Drugs are FDA-approved; compounded versions carry additional risk | | NABP VIPPS Pharmacy | Third-party; verify separately | Patients must confirm pharmacy accreditation independently | | FTC Negative Option Compliance | Disputed (consumer complaints) | Cancellation process is a documented patient concern |